Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Merck & Co. presents macrocyclic peptide MK-0616 as a potent, oral PCSK9 inhibitor | BioWorld
Merck Oncology Investor Event
Why Merck's PCSK9 Inhibitors Are a Big Deal - Drug Hunter
Merck bags global rights to NGM NASH drug, plans phase 2b trial | Fierce Biotech
Merck Investigational Anticoagulant Therapy MK-2060 gets USFDA fast track designation
Merck's MK-3475 Biologics License Application Up For FDA Priority Review
Why Merck's PCSK9 Inhibitors Are a Big Deal - Drug Hunter
Chemical structures of M1-mAChR allosteric ligands developed by Merck... | Download Scientific Diagram
Merck & Co. presents macrocyclic peptide MK-0616 as a potent, oral PCSK9 inhibitor | BioWorld
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab ( MK-4280) and Pembrolizumab (
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer | Journal of Medicinal Chemistry
An Unrelenting Disaster Zone”: Merck's Alzheimer's Drug Fails in Phase III | BioSpace
Merck & Co., Ridgeback Biotherapeutics, and Drug Innovations at Emory (DRIVE) – Molnupiravir (MK-4482, EIDD-2801)
Ralph on Twitter: "$NGM has 2 NASH drugs in its pipeline, MK-3655, an FGFR1c/KLB agonistic Ab (licensed to Merck) and aldafermin, an FGF19 Analogue (failed). Latest presentation: https://t.co/PogNcyVSNJ No position https://t.co/ohQ9pq8YZ9" /
Molnupiravir - Wikipedia
In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile
Merck Pauses Development Of MK-8507 In HIV Infection
Merck & Co. Has Come Up With Very Powerful Pill Against 'Bad' Cholesterol • BioPharma Media
MK-2048 - Wikipedia
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer | Journal of Medicinal Chemistry
Merck & Co. Has Come Up With Very Powerful Pill Against 'Bad' Cholesterol • BioPharma Media
Chemical structure of compound MK-8931. MK-8931 is developed at Merck... | Download Scientific Diagram
Merck's MK-0616 looks set to become first oral PCSK9 inhibitor in dysl
Merck swallows $2.9B write-down of experimental hep C drug as market plummets | Fierce Pharma
ESMO 2022: Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006
